TERN Share Price Performance
US$36.60
32.15 (722.47%)
62.9% undervalued intrinsic discount
US$98.57
Fair Value
Price US$36.60
AverageSven US$98.57
Fair ValueUS$98.57
Share Pricen/a
Terns Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
TERN Community Narratives
AV
Fair Value US$98.57 62.9% undervalued intrinsic discount
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57 Terns Pharmaceuticals (TERN) is fundamentally undervalued based on the clinical profile of its lead oncology asset, TERN-701. The latest data establish a clear trajectory for market leadership in Chronic Myeloid Leukemia (CML), justifying an intrinsic valuation target of 98.57 per share.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AV
US$98.57
62.9% undervalued intrinsic discount
AverageSven's Fair Value
Profit Margin
15.39%
Future PE
22.83x
Price in 2030
US$0
Trending Discussion
Recently Updated Narratives
AV
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
Fair Value: US$98.57 62.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Terns Pharmaceuticals, Inc. Key Details
About TERN
- Founded
- 2016
- Employees
- 59
- CEO
- WebsiteView website
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
